ARCA biopharma (ABIO) Receives Patent for Methods of Treatment with Bucindolol
ARCA biopharma Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, has been awarded a patent from the U.S. Patent and Trademark Office (USPTO) for the company’s methods of treating patients with bucindolol based on genetic targeting and focused on a specific genotype (homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor). The patent entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting” provides patent protection in the United States for the company’s approach to treating patients with bucindolol. Dr. Michael Bristow, CEO of ARCA biopharma, emphasized the challenges surrounding cardiovascular diseases and how new therapies…